# A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

> **NCT02859259** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 14 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** BMS-663068 (1 tablet at 600 mg)
- **DRUG:** BMS-663068 (4 tablets at 150 mg each tablet)

## Key facts

- **NCT ID:** NCT02859259
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-12
- **Primary completion:** 2016-08-12
- **Final completion:** 2016-08-12
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02859259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02859259, "A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02859259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*